Displaying 21 - 40 of 237
Download
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published
MHRA-101771-PIP01-24
  • SEMAGLUTIDE
  • Prevention of cardiovascular events in patients with atherosclerosis
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Cardiovascular Diseases
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101718-PIP01-24
  • Human alpha-1-proteinase inhibitor immunoglobulin G fusion protein, recombinant
  • Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin
  • Pneumology - Allergology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101704-PIP01-24
  • Nucresiran sodium
  • Treatment of transthyretin amyloidosis
  • Neurology
  • Cardiovascular Diseases
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101676-PIP01-24
  • HUMAN ANTI-D IMMUNOGLOBULIN
  • Prevention of Rhesus (Rh) isoimmunisation
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Haematology-Hemostaseology
  • Other: Immunology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101674-PIP01-24
  • Linvoseltamab
  • Treatment of multiple myeloma
  • LYNOZYFIC
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101707-PIP01-24
  • AMG 193
  • Treatment of non-small cell lung cancer
  • Not available at present
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101729-PIP01-24
  • Ifinatamab deruxtecan
  • Treatment of prostate malignant neoplasms
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101730-PIP01-24
  • Ifinatamab deruxtecan
  • Treatment of oesophageal cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101660-PIP01-24
  • RUXOLITINIB PHOSPHATE
  • Treatment of prurigo nodularis
  • OPZELURA
  • OPZELURA
  • OPZELURA
  • OPZELURA
  • Dermatology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101412-PIP01-24
  • Pridopidine hydrochloride
  • Treatment of amyotrophic lateral sclerosis (ALS)
  • Nurzigma
  • Neurology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101770-PIP01-24
  • SEMAGLUTIDE
  • Treatment of Chronic Kidney Disease
  • Ozempic
  • Ozempic
  • Ozempic
  • Ozempic
  • Ozempic
  • Uro-Nephrology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101694-PIP01-24
  • Human IgG1 monoclonal antibody targeting amyloid transthyretin
  • Treatment of transthyretin-mediated amyloidosis
  • Neurology
  • Cardiovascular Diseases
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101664-PIP01-24
  • SECUKINUMAB
  • Treatment of polymyalgia rheumatica
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Cosentyx
  • Immunology -Rheumatology-Transplantation
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101654-PIP01-24
  • Volrustomig
  • Treatment of head and neck epithelial malignant neoplasms
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101605-PIP01-24
  • Telisotuzumab adizutecan
  • Treatment of lung carcinoma (small cell and non-small cell carcinoma)
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101702-PIP01-24
  • Modified messenger ribonucleic acid encoding individual patient-specific tumour neoantigens V940 (mRNA-4157)
  • Treatment of melanoma
  • Not available at present
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101457-PIP01-24
  • Acasunlimab
  • Treatment of lung cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101746-PIP01-24
  • H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt
  • Treatment of pancreatic cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101411-PIP01-24
  • Erdafitinib
  • Treatment of urothelial carcinoma
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101680-PIP01-24
  • CICLOSPORIN
  • Treatment of dry eye disease (DED)
  • Vevizye
  • Vevizye
  • Vevye
  • Ophthamology
 W: decision granting a waiver in all age groups for the listed condition(s). No
Download XLSX